PDCD1 and non-small cell lung carcinoma: Therefore, we performed this meta-analysis, systematically combining data from published clinical trials, to evaluate the efficacy and safety of anti-PD-1/PD-L1 antibodies in previously treated advanced NSCLC as compared to docetaxel.